GIANT BIOGENE was listed on the Hong Kong Stock Exchange on November 4, 2022. In the second half of 2021, BA Capital participated in the Pre-IPO round of financing for GIANT BIOGENE, which was also the company's only financing round prior to its IPO.
As an enterprise built upon a synthetic biology platform, GIANT BIOGENE is tapping into a market with an estimated potential of nearly RMB one trillion. The company has maintained an annual revenue growth rate of approximately 50% annually for three consecutive years. Its primary business segments include functional skincare products, wound dressings, and health supplements, with core brands such as Comfy and Collgene.
The advancement of synthetic biology is set to reshape the skincare industry once again and extend further into the broader consumer market. In skincare, a product’s moat lies not only in owning exclusive raw materials—the most enduring advantage—but also in the proprietary knowledge of how to formulate and apply them. GIANT BIOGENE has built precisely this moat.
By the end of 2024, GIANT BIOGENE had 188 active research projects and held 167 patents and patent applications.
In March 2025, GIANT BIOGENE was once again certified by Euromonitor International, a world-renowned market research authority, as the global leader in recombinant collagen. This renewed certification underscores the company’s two decades of technological leadership. It also reflects the broad market and consumer acceptance of products based on this core ingredient.
Distribution channels serve as the bridge between products and consumers. GIANT BIOGENE employs a dual-track sales strategy targeting both "medical institutions and mass consumers," implementing an omnichannel approach to continuously expand the breadth and depth of its product coverage. Through differentiated operational strategies, the company precisely reaches and serves diverse consumer segments.
As of the end of 2024, GIANT BIOGENE's products had entered approximately 1,700 public hospitals, approximately 3,000 private hospitals and clinics, 650 pharmacy chains, and nearly 6,000 CS/KA retail stores across China through offline direct and distribution channels.
Explaining its confidence in GIANT BIOGENE, BA Capital stated:
BA Capital's investment in GIANT BIOGENE is based on its synthetic biology platform, the long-established R&D team and patent portfolio, endorsement and recommendation by thousands of hospital channels, brand recognition and reputation, and its globally leading industry position.
For over twenty years, GIANT BIOGENE has essentially focused on one thing: building barriers through scientific research and continuously pursuing product excellence.
In the beauty and skincare sector, few companies integrate R&D, raw material development, branding, production, channels, and marketing as seamlessly as GIANT BIOGENE. The functional premium supported by R&D, combined with the cost efficiency gains from self-production, ultimately results in high profitability. R&D is not merely a marketing tool; GIANT BIOGENE’s strategic determination to sustain R&D through challenging periods reflects the brand’s resilience and long-term vision.
Fundamentally, BA Capital is optimistic about the Chinese pursuit of beauty and the rise of the domestic ecosystem amid the emergence of a new generation of consumers. The firm believes that amid macroeconomic pressures and intensifying industry competition, consumers will gravitate toward products that deliver true core value.
Over the past five years, GIANT BIOGENE's gross profit margin has consistently remained above 80%. For GIANT BIOGENE, 2025 marks the first year of its brand's global expansion, with Comfy entering the Malaysian and South Korean markets. Beyond channel expansion, Comfy is building an overseas social media ecosystem and collaborating with global influencers on traceability initiatives—showcasing the technological strength of Chinese skincare brands worldwide.
